Welcome
Support Centre
02 September 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Behavioural therapy of depression: a randomised controlled trial of behavioural therapy of depression delivered by specifically trained generic mental health staff
Source of recordUK Trials
ISRCTNISRCTN27045243
Date ISRCTN assigned30/11/2007
Local reference number(s)N/A
Public titleBehavioural therapy of depression: a randomised controlled trial of behavioural therapy of depression delivered by specifically trained generic mental health staff
Scientific title
AcronymN/A
Disease/condition/study domainDepression
Study hypothesis1. After 12 weeks of treatment, depressed patients in the Behavioural Therapy (BT) group will have superior clinical outcomes (measured by Beck Depression Inventory) compared to those in the monitoring control arm
2. Patient satisfaction will be superior in BT than in monitoring control arm
3. BT will be a cost effective intervention
Design/methodologyRandomised controlled trial
Research ethics reviewEthics approval to be submitted to the North East Research Ethics Committee (REC) in November 2007.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Patients aged 18+
2. A General Practitioner (GP) diagnosis of depression
3. On no antidepressant medication or have been on a stable dose for at least 6 weeks
4. Consent to take part in the study

Eligibility will be assessed by trained research interviewer using the Clinical Interview Schedule Revised (CSIR) prior to randomisation.
Participants - exclusion criteria1. Currently actively suicidal
2. Have psychosis, diagnosis of bi-polar disorder or organic brain disease
3. Use alcohol or non prescription drugs requiring a primary clinical intervention
Patient information material
Anticipated start date01/04/2008
Anticipated end date01/04/2009
Status of trialOngoing
Target number of participants60
InterventionsBT: Patients will receive a 45 minute assessment and up to twelve 30 - 45 minute BT therapy sessions from a mental health worker using structured materials following a BT protocol. BT consists of a structured programme of reducing the frequency of negatively reinforced avoidant behaviours in parallel with increasing the frequency of positively reinforcing behaviours to improve functioning and raise mood.

The control group is a monitoring control arm. Participants will be placed on a 12 week monitoring control group. They will be contacted fortnightly by phone for approximately 10 minutes. Depression severity will be assesed via the Patient Health Questionaire. Should clinical indications suggest further intervention is required, patients will be asked to contact their GP. At 12 weeks participants in this arm will be offered intervention as per BT treatment arm.
Primary outcome measure(s)Assessments will be conducted by a research worker blind to treatment allocation at pre-treatment and 12 weeks follow up. The primary clinical outcome will be depression symptom level as measured by the Beck Depression inventory.
Secondary outcome measure(s)Secondary outcome measures include:
1. The Social Adjustment Scale
2. Measures of treatment satisfaction, assessed using the 8-item Client Satisfaction Questionnaire (CSQ8)
3. Service utilisation data collected on frequency of primary, secondary and tertiary service use via patient diaries and questionnaires
4. Health utility data, measured by the Euroqol

All measurements will be collected pre treatment and at 12 weeks.
Sources of fundingTees Esk & Wear Valleys NHS Trust (UK)
Sponsor nameTees Esk & Wear Valleys NHS Trust (UK)
Sponsor detailsResearch and Development Office
TAD Centre
Ormesby Road
Middlesbrough
United Kingdom
TS3 7SF
Sponsor telephone+44 (0)1642 516981
Sponsor emailj.g.reilly@dur.ac.uk
Sponsor websitehttp://www.tewv.nhs.uk/
Contact nameMr David Ekers
Contact detailsHealth Centre
Newcastle Road
Chester Le Street
Co Durham
United Kingdom
DH3 3UR
Contact telephone+44 (0)191 333 6000
Contact emaildavid.ekers@dur.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN27045243
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central